Deleterious impact of mild anemia on survival of young adult patients (age 45 ± 14 years) with idiopathic dilated cardiomyopathy: Data from the Trieste Cardiomyopathies Registry

Heart and Lung: Journal of Acute and Critical Care

Volumn 40, Issue 5, 2011, Pages 454-461

  Aleksova, Aneta ^a   Barbati, Giulia ^a   Merlo, Marco ^a   Stolfo, Davide ^a   Sabbadini, Gastone ^a   Di Lenarda, Andrea ^b   Sinagra, Gianfranco ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b Cardiovascular Center   (Italy)

Author keywords

Anaemia; Heart Failure; Idiopathic Dilated Cardiomyopathy; Prognosis

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL;

ADULT; AGED; ANEMIA; ARTICLE; COHORT ANALYSIS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE REGISTRY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOMYOPATHY, DILATED; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 80052268707     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2010.06.001     Document Type: Article

References (35)

1. Bardy G.H., Lee K.L., Mark D.B., et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225-237.
2. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Eur Heart J 2008, 29:2388-2442. Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology.
3. Anand I., McMurray J.J., Whitmore J., et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004, 110:149-154.
4. Ralli S., Horwich T.B., Fonarow G.C. Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J 2005, 150:1220-1227.
5. Felker G.M., Shaw L.K., Stough W.G., O'Connor C.M. Anemia in patients with heart failure and preserved systolic function. Am Heart J 2006, 151:457-462.
6. Grigorian Shamagian L., Varela R.A., Garcia-Acuna J.M., Mazon R.P., Virgos L.A., Gonzalez-Juanatey J.R. Anaemia is associated with higher mortality among patients with heart failure with preserved systolic function. Heart 2006, 92:780-784.
7. Newton J.D., Squire I.B. Glucose and haemoglobin in the assessment of prognosis after first hospitalisation for heart failure. Heart 2006, 92:1441-1446.
8. Schou M., Gustafsson F., Kistorp C.N., Corell P., Kjaer A., Hildebrandt P.R. Prognostic usefulness of anemia and N-terminal pro-brain natriuretic peptide in outpatients with systolic heart failure. Am J Cardiol 2007, 100:1571-1576.
9. Kosiborod M., Curtis J.P., Wang Y., et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med 2005, 165:2237-2244.
10. Formiga F., Chivite D., Castaner O., Manito N., Ramon J.M., Pujol R. Anemia in new-onset congestive heart failure inpatients admitted for acute decompensation. Eur J Intern Med 2006, 17:179-184.
11. Gardner R.S., Chong K.S., Morton J.J., McDonagh T.A. N-terminal brain natriuretic peptide, but not anemia, is a powerful predictor of mortality in advanced heart failure. J Card Fail 2005, 11:S47-S53.
12. Silva R.P., Barbosa P.H., Kimura O.S., et al. Prevalence of anemia and its association with cardio-renal syndrome. Int J Cardiol 2007, 120:232-236.
13. Tigen K., Karaahmet T., Cevik C., Gurel E., Mutlu B., Basaran Y. Prognostic utility of anemia and pro-B-type natriuretic peptide in patients with nonischemic dilated cardiomyopathy and normal renal function. Am J Med Sci 2009, 337:109-115.
14. Richardson P., McKenna W., Bristow M., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996, 93:841-842.
15. Aretz H.T. Myocarditis: the Dallas criteria. Hum Pathol 1987, 18:619-624.
16. Nutritional anaemias: report of a WHO Scientific Group 1968, World Health Organization, World Health Organization, Geneva, Switzerland.
17. Spain M.G., Smith M.D., Grayburn P.A., Harlamert E.A., DeMaria A.N. Quantitative assessment of mitral regurgitation by Doppler color flow imaging: angiographic and hemodynamic correlations. J Am Coll Cardiol 1989, 13:585-590.
18. Appleton C.P., Hatle L.K., Popp R.L. Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol 1988, 12:426-440.
19. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
20. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
21. McCullough P.A., Lepor N.E. Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med 2005, 6(Suppl 3):S4-S12.
22. Tang Y.D., Katz S.D. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006, 113:2454-2461.
23. Androne A.S., Katz S.D., Lund L., et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003, 107:226-229.
24. Ishani A., Weinhandl E., Zhao Z., et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2005, 45:391-399.
25. Komajda M., Anker S.D., Charlesworth A., et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006, 27:1440-1446.
26. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002, 91:988-998.
27. Anand I.S., Rector T., Deswal A., et al. Relationship between proinflammatory cytokines and anemia in heart failure. Eur Heart J 2006, 27(Suppl 1). 485.
28. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103:2055-2059.
29. Torre-Amione G., Bozkurt B., Deswal A., Mann D.L. An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol 1999, 14:206-210.
30. Macdougall I.C., Cooper A.C. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002, 17(Suppl 11):39-43.
31. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
32. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998, 18:555-559.
33. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002, 39:1780-1786.
34. Anand I.S., Chandrashekhar Y., Ferrari R., Poole-Wilson P.A., Harris P.C. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 1993, 70:357-362.
35. McMurray J.J., Anand I.S., Diaz R., et al. RED-HF Committees and Investigators. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009, 11:795-801.